UK-based drug companies AstraZeneca and GSK could be affected by Trump’s next decision, as Karl Matchett reports ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

The pharmaceutical company said Thursday that the U.S. Advisory Committee on Immunization Practices had issued a positive recommendation on GSK's 5-in-1 meningitis vaccine Penmenvy as well as its ...

The recommendation builds on the committee’s June 2024 vote for the use of RSV vaccines for people aged 60 to 74 at high risk ...

GSK said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities ...

GSK received approval from U.K.'s medicines regulatory body to bring its blood-cancer blockbuster candidate Blenrep back to the market, enabling the British pharma giant to expand its oncology ...

GSK’s blood cancer drug Blenrep won regulatory approval in the U.K., marking the medicine’s return to the market after it was ...

GSK (GSK) said it is “pleased” that the Advisory Committee on Immunization Practices voted in favor of recommending the use of RSV vaccines ...

GSK (GSK) announced that the US CDC’s Advisory Committee on Immunization Practices has voted to recommend use of Penmvevy as part of the ...

RSV vaccines could get broader CDC backing for adults aged 50-59 at risk after an endorsement from an agency's expert panel. Read more here.

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

The agency is missing deadlines and not responding to biotech companies, forcing some to push back clinical trials.